Demonstration of dose response of flurbiprofen lozenges with the sore throat pain model

Clin Pharmacol Ther. 2002 May;71(5):375-80. doi: 10.1067/mcp.2002.124079.

Abstract

The dose response of flurbiprofen lozenges (2.5, 5.0, and 12.5 mg) was evaluated in the treatment of sore throat. A refined version of the sore throat pain model showed that 12.5 mg flurbiprofen was significantly more effective than placebo at providing total pain relief and reducing throat soreness (p <.05). Flurbiprofen, 5.0 mg, was more effective than placebo for the reduction of throat soreness and the sensation of throat swelling (P <.05). The 2.5-mg flurbiprofen lozenge was indistinguishable from placebo. For every milligram of increase in the dose of flurbiprofen, there was an approximately 0.3-unit increase in total pain relief (P <.05). Flurbiprofen lozenges in all 3 dosages were well tolerated. Flurbiprofen lozenges are effective for sore throat at a dose between 5.0 mg and 12.5 mg; the sore throat pain model is a sensitive assay for demonstration of the dose-response relationship of an analgesic agent.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Analgesics / administration & dosage*
  • Analgesics / adverse effects
  • Analysis of Variance
  • Chi-Square Distribution
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Flurbiprofen / administration & dosage*
  • Flurbiprofen / adverse effects
  • Humans
  • Male
  • Pain Measurement / drug effects
  • Pain Measurement / statistics & numerical data
  • Pharyngitis / drug therapy*

Substances

  • Analgesics
  • Flurbiprofen